Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study

Objective: Our aim was to evaluate the effect of adalimumab on work productivity measures, overall activity impairment, and sleep quality in patients with active moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated in routine care settings in Greece and determine factors associated with work impairment and sleep disturbance. Methods: Patients with active moderate to severe RA ( n = 184), PsA ( n = 166), and AS ( n = 150) were enrolled in this 24-month, prospective, observational study at 80 hospital outpatient clinics and private practices throughout Greece. Patients received adalimumab alone or in combination with standard antirheumatic therapies according to routine care. Work productivity and sleep were assessed through two patient-reported outcome measures: the Work Productivity and Activity Impairment–General Health questionnaire and the Medical Outcomes Study Sleep Scale (MOS-SS). Pearson correlation coefficients were estimated to assess the association of work impairment and sleep disturbances with disease activity scores. Results: In the overall population, adalimumab significantly lowered absenteeism [mean (95% confidence interval) reduction, 18.9% (13.3–24.5%); n = 100]; presenteeism [40.0% (33.8–46.3%); n = 98], overall work productivity impairment [46.8% (40.4–53.2%); n = 94], activity impairment [47.0% (44.3–49.6); n = 421], and the MOS-SS sleep problems index [31.6 (29.5–34.1); n = 421] after 24-month treatment ( p < 0.001). Significant improvements were also noted across the RA, PsA, and AS subpopulations ( p < 0.05). Improvements in overall work impairment and sleep disturbance positively correlated with improvements in disease activity measures. Conclusion: Adalimumab improves work productivity and sleep problems while lowering disease activity in patients with moderate to severe RA, PsA, and AS managed in real-world settings.

Download Full-text

THU0121 Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.649 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A203.1-A203 ◽

Cited By ~ 1

Author(s):

A. Okada ◽

A. Kawakami ◽

T. Fukuda ◽

T. Hidaka ◽

T. Ishii ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cohort Study ◽

Large Scale ◽

Radiographic Progression ◽

Daily Practice ◽

Japanese Patients ◽

Longitudinal Cohort Study ◽

Disease Modifying ◽

Prospective Longitudinal ◽

Prospective Longitudinal Cohort

Download Full-text

Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: A subgroup analysis of Japanese patients from a large international cohort study (SENSE)

PLoS ONE ◽

10.1371/journal.pone.0259389 ◽

2021 ◽

Vol 16 (11) ◽

pp. e0259389

Author(s):

Yutaka Kawahito ◽

Yuya Takakubo ◽

Akio Morinobu ◽

Naoko Matsubara ◽

Orsolya Nagy ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Side Effects ◽

Combination Therapy ◽

Treatment Adherence ◽

Treatment Satisfaction ◽

Work Productivity ◽

Japanese Patients ◽

Oral Medication ◽

Total Work ◽

Global Satisfaction

Objective To evaluate treatment satisfaction, disease outcomes, and perspectives of patients with poorly controlled rheumatoid arthritis (RA) treated with conventional synthetic, targeted synthetic, or biologic disease-modifying antirheumatic drugs (DMARDs), we conducted a subgroup (post hoc) analysis of Japanese patients participating in the SENSE study. Methods Data for Japanese patients (n/N = 118/1629) from the global, multicenter, cross-sectional, observational SENSE study were analyzed. The primary endpoint was the global satisfaction subscore assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. Other patient-reported outcomes included self-reported RA medication adherence and Work Productivity and Activity Impairment-RA. Patient perspectives included patients’ expectations and preference of pharmacologic treatment. Results Median (range) age and RA disease duration were 67.0 (18.0–87.0) years and 8 (0.0-54) years, respectively; 81.4% of patients were female. Mean (SD) TSQM global satisfaction subscore was 56.8 (17.5), and only 5.9% of patients reported good satisfaction with treatment (TSQM global ≥80). Mean (SD) self-reported treatment adherence using VAS was high (93.5% [13.8%]). Mean (SD) total work productivity impairment was 45.6% (32.0%); presenteeism contributed toward more total work productivity impairment (43.9% [30.4%]) than absenteeism (8.3% [24.4%]). Patients expected improvement in all parameters from their treatment, especially improvement in joint symptoms. Most patients (80.7%) preferred oral medication and 18.7% preferred monotherapy. Patient acceptability of potentially manageable side effects was high (7.5%-34.0%). Although most patients (81.3%) found combination therapy acceptable, 43.2% were receiving DMARD monotherapy. Conclusion Although most Japanese patients with RA with moderate-to-high disease activity were dissatisfied with their current DMARD treatment, high treatment adherence, high acceptability of combination therapy, high acceptability of manageable potential side effects, and preference for oral medication were reported. Data support the development of a more individualized and patient-centric approach for RA treatment.

Download Full-text

FRI0124 Assessment of work productivity and activity impairment in patients with rheumatoid arthritis based on the institute of rheumatology rheumatoid arthritis (IORRA) cohort database

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1251 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A412.1-A412

Author(s):

E. Tanaka ◽

E. Inoue ◽

D. Hoshi ◽

K. Shidara ◽

N. Sugimoto ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Work Productivity ◽

Activity Impairment

Download Full-text

Validity of the work productivity and activity impairment questionnaire - general health version in patients with rheumatoid arthritis

Arthritis Research & Therapy ◽

10.1186/ar3141 ◽

2010 ◽

Vol 12 (5) ◽

pp. R177 ◽

Cited By ~ 93

Author(s):

Wei Zhang ◽

Nick Bansback ◽

Annelies Boonen ◽

Adam Young ◽

Amitabh Singh ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

General Health ◽

Work Productivity ◽

Activity Impairment

Download Full-text

AB0927-PARE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH SAPHO SYNDROME

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.484 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 1484.3-1485

Author(s):

L. Gong ◽

C. Li

Keyword(s):

Rheumatoid Arthritis ◽

Irritable Bowel Syndrome ◽

Ankylosing Spondylitis ◽

General Health ◽

Productivity Loss ◽

Work Productivity ◽

Sapho Syndrome ◽

Activity Impairment ◽

Irritable Bowel ◽

Disease Specific

Background:Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare disease, characterized by osteoarticular and cutaneous manifestations. Osteitis and hyperostosis are regarded as the core pathophysiological changes of SAPHO syndrome [1], which may lead to bone pain and loss of motor function. The Work Productivity and Activity Impairment (WPAI) questionnaire is an instrument to measure the impact of the disease on work productivity and activity, subsequently adapted for ankylosing spondylitis [2], rheumatoid arthritis [3], irritable bowel syndrome [4], and other chronic diseases [5]. However, no study has investigated the work productivity of patients with SAPHO syndrome.Objectives:The purpose of this study is to give an overview of work productivity loss in SAPHO patients through the work productivity and activity impairment (WPAI) questionnaire and investigate the relationship between the WPAI and other disease-related indicators.Methods:Patients for this cross-sectional study were recruited from Peking Union Medical College Hospital (Beijing, China). The questionnaires incorporating the WPAI were administered, along with demographic data, disease-specific measures, and general health variables. The construct validity of WPAI was evaluated by the correlations between WPAI outcomes and other measures. Wilcoxon rank-sum tests and non-parametric Kruskal-Wallis tests were used for comparison of WPAI outcomes between known-groups.Results:A total of 376 patients were included and 201 patients (53.5%) were employed. The median (interquartile range [IQR]) of absenteeism, presenteeism, work productivity loss and activity impairment were 0% (0-13%), 20% (0-40%), 20% (0-52%) and 30% (0-50%), respectively. All WPAI outcomes showed moderate to strong correlations to other generic and disease-specific measures (|r| =0.43-0.75), except for absenteeism. Increasing disease activity and worse health status are significantly associated with higher impairment of work productivity and activity.Conclusion:This study highlights the negative effects of SAPHO syndrome on patients’ work productivity and activity, indicating a good construct validity and discriminative ability of WPAI. For reducing the economic burden, it is important to improve the patients’ work productivity and daily activity with active intervention.References:[1]Liu S, Tang M, Cao Y, Li C. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update. Therapeutic advances in musculoskeletal disease. 2020;12:1759720x20912865.[2]Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford, England). 2010;49(4):812-819.[3]Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis. Arthritis research & therapy. 2010;12(5):R177.[4]Frandemark A, Tornblom H, Jakobsson S, Simren M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. The American journal of gastroenterology. 2018;113(10):1540-1549.[5]Enns MW, Bernstein CN, Kroeker K, Graff L, Walker JR, Lix LM, et al. The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. PloS one. 2018;13(6):e0198975.Disclosure of Interests:None declared

Download Full-text

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Arthritis Research & Therapy ◽

10.1186/s13075-021-02590-z ◽

2021 ◽

Vol 23 (1) ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hiroyuki Izutsu ◽

Yuichiro Kaneko ◽

Daisuke Kato ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Disease Activity ◽

Daily Activity ◽

Global Assessment ◽

Work Productivity ◽

Phase 3 ◽

Activity Impairment ◽

Link Type ◽

Asian Patients ◽

Domain Scores

Abstract Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated the effect of peficitinib on patient- and physician-reported outcomes in Asian patients with RA and an inadequate response to prior disease-modifying antirheumatic drugs (DMARDs). Methods Patients from two randomized, placebo-controlled, double-blind, phase 3 trials (RAJ3 and RAJ4) received once-daily peficitinib 100 mg, peficitinib 150 mg, or placebo, alone or in combination with DMARDs (RAJ3), or in combination with methotrexate (RAJ4). Mean changes in Work Productivity and Activity Impairment (WPAI) questionnaire domain scores from baseline, and percentages of patients achieving minimal clinically important differences (MCIDs) for patient- and physician-reported outcomes (WPAI, Health Assessment Questionnaire – Disability Index [HAQ-DI], and Subject’s Global Assessment of Pain [SGAP]), and Physician’s Global Assessment of disease activity (PGA) were evaluated at weeks 4, 8, 12, and 12/early termination (ET). Results Data from 1025 patients were analyzed. At week 12/ET in both studies, patients who received peficitinib 100 mg or 150 mg reported significantly improved WPAI domain scores from baseline (except for absenteeism in RAJ4) compared with placebo (both doses, p<0.05). A higher proportion of peficitinib- versus placebo-treated patients achieved MCID in WPAI, HAQ-DI, SGAP, and PGA in studies RAJ3 and RAJ4. Significant differences with peficitinib versus placebo were evident in both studies as early as week 4 in HAQ-DI (peficitinib 150 mg only), SGAP, and PGA, and week 8 in WPAI loss of work productivity and daily activity impairment. At week 12/ET, significantly higher proportions of patients receiving peficitinib versus placebo achieved MCID in HAQ-DI, SGAP, PGA, and WPAI domains of presenteeism (RAJ3 only), loss of work productivity (RAJ3 only), and daily activity impairment (p<0.05 for all comparisons). Conclusions Peficitinib 100 mg or 150 mg administered daily over 12 weeks resulted in clinically meaningful improvements in outcomes that are important to RA patients, including pain, physical function, and work productivity and activity. These observations were reinforced through similar improvements in physicians’ rating of disease activity. Trial registration RAJ3: ClinicalTrials.gov, NCT02308163, registered 4 December 2014. RAJ4: ClinicalTrials.gov, NCT02305849, registered 3 December 2014.

Download Full-text